JP2007525207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525207A5 JP2007525207A5 JP2006541642A JP2006541642A JP2007525207A5 JP 2007525207 A5 JP2007525207 A5 JP 2007525207A5 JP 2006541642 A JP2006541642 A JP 2006541642A JP 2006541642 A JP2006541642 A JP 2006541642A JP 2007525207 A5 JP2007525207 A5 JP 2007525207A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- recombinant polynucleotide
- cell surface
- motif
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 79
- 229920001184 polypeptide Polymers 0.000 claims 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims 77
- 210000004027 cell Anatomy 0.000 claims 42
- 108091033319 polynucleotide Proteins 0.000 claims 40
- 102000040430 polynucleotide Human genes 0.000 claims 40
- 239000002157 polynucleotide Substances 0.000 claims 40
- 238000000034 method Methods 0.000 claims 20
- 238000005192 partition Methods 0.000 claims 18
- 230000002163 immunogen Effects 0.000 claims 8
- 239000013612 plasmid Substances 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 102000004257 Potassium Channel Human genes 0.000 claims 3
- 230000030583 endoplasmic reticulum localization Effects 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 108020001213 potassium channel Proteins 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000005595 Chronic Idiopathic Jaundice Diseases 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 201000004943 Dubin-Johnson syndrome Diseases 0.000 claims 2
- 208000011514 Familial renal glucosuria Diseases 0.000 claims 2
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 claims 2
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims 2
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000031852 maintenance of location in cell Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004481 post-translational protein modification Effects 0.000 claims 2
- 208000007278 renal glycosuria Diseases 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108010036221 Aquaporin 2 Proteins 0.000 claims 1
- 102000011899 Aquaporin 2 Human genes 0.000 claims 1
- 102000010637 Aquaporins Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 230000004989 O-glycosylation Effects 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 102100040756 Rhodopsin Human genes 0.000 claims 1
- 108090000820 Rhodopsin Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 238000010448 genetic screening Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52438003P | 2003-11-21 | 2003-11-21 | |
| US60/524,380 | 2003-11-21 | ||
| PCT/US2004/039285 WO2005053811A2 (en) | 2003-11-21 | 2004-11-22 | Biomolecule partition motifs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007525207A JP2007525207A (ja) | 2007-09-06 |
| JP2007525207A5 true JP2007525207A5 (enExample) | 2008-01-24 |
| JP4790624B2 JP4790624B2 (ja) | 2011-10-12 |
Family
ID=34652267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541642A Expired - Fee Related JP4790624B2 (ja) | 2003-11-21 | 2004-11-22 | 生体分子パーティションモチーフ及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7732165B2 (enExample) |
| EP (1) | EP1701772A4 (enExample) |
| JP (1) | JP4790624B2 (enExample) |
| CN (1) | CN1997749A (enExample) |
| AU (1) | AU2004294933B2 (enExample) |
| WO (1) | WO2005053811A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759354B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
| US20070053996A1 (en) | 2005-07-22 | 2007-03-08 | Boyden Edward S | Light-activated cation channel and uses thereof |
| US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US7763606B2 (en) * | 2005-10-27 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| WO2008101128A1 (en) | 2007-02-14 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
| WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
| KR20180102215A (ko) * | 2007-11-27 | 2018-09-14 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도 |
| SG189813A1 (en) | 2008-04-23 | 2013-05-31 | Univ Leland Stanford Junior | Systems, methods and compositions for optical stimulation of target cells |
| JP5890176B2 (ja) | 2008-05-29 | 2016-03-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | セカンドメッセンジャーを光制御するためのセルライン、システム、および方法 |
| AU2009260029B2 (en) | 2008-06-17 | 2016-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
| EP2303405A4 (en) | 2008-06-17 | 2017-12-27 | The Board of Trustees of the Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
| US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
| CA2754741C (en) | 2009-03-11 | 2019-02-12 | Augurex Life Sciences Corporation | Compositions and methods for characterizing arthritic conditions |
| US9134323B2 (en) | 2009-12-01 | 2015-09-15 | The Rockefeller University | Antibody that specifically binds to an epitope in the tureet region of a human Kir channel |
| JP5866332B2 (ja) | 2010-03-17 | 2016-02-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 感光性イオンを通過させる分子 |
| CA2817175C (en) | 2010-11-05 | 2019-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light using lanthanide-doped nanoparticles for use in optogenetic methods |
| CN106106368A (zh) | 2010-11-05 | 2016-11-16 | 斯坦福大学托管董事会 | 光控cns功能障碍 |
| WO2012061681A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University. | Control and characterization of memory function |
| EP3486253A1 (en) | 2010-11-05 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
| US9992981B2 (en) | 2010-11-05 | 2018-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
| CN103491770B (zh) | 2010-11-05 | 2016-06-08 | 斯坦福大学托管董事会 | 稳定阶跃函数视蛋白及其使用方法 |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| BR112014009536A2 (pt) | 2011-10-21 | 2017-04-18 | Augurex Life Sciences Corp | antígenos derivados de 14-3-3 xitrulinada e usos dos mesmos no diagnóstico de artrite reumatoide |
| EP3524676A1 (en) | 2011-12-16 | 2019-08-14 | The Board of Trustees of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
| ES2628006T3 (es) | 2012-02-21 | 2017-08-01 | Circuit Therapeutics, Inc. | Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico |
| US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
| US10974064B2 (en) | 2013-03-15 | 2021-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
| WO2014179331A2 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
| CA2921221A1 (en) | 2013-08-14 | 2015-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
| WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
| CN111870700B (zh) * | 2020-08-12 | 2021-10-19 | 中国科学院昆明动物研究所 | 十八烷基化修饰的r18-7aa多肽及其衍生多肽的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856155A (en) | 1996-02-23 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Compounds and related methods for modulating potassium ion channels and assays for such compounds |
| WO1997044491A1 (en) | 1996-05-22 | 1997-11-27 | The Johns Hopkins University | Methods of detection utilizing modified bacteriophage |
| AU7410998A (en) | 1996-11-26 | 1998-06-22 | Johns Hopkins University, The | Ligand detection system and methods of use thereof |
| CA2382483A1 (en) | 1999-08-20 | 2001-03-01 | Johns Hopkins University School Of Medicine | Methods and compositions for the construction and use of fusion libraries |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
-
2004
- 2004-11-22 AU AU2004294933A patent/AU2004294933B2/en not_active Expired - Fee Related
- 2004-11-22 JP JP2006541642A patent/JP4790624B2/ja not_active Expired - Fee Related
- 2004-11-22 EP EP04817873A patent/EP1701772A4/en not_active Withdrawn
- 2004-11-22 WO PCT/US2004/039285 patent/WO2005053811A2/en not_active Ceased
- 2004-11-22 CN CNA200480040802XA patent/CN1997749A/zh active Pending
-
2006
- 2006-05-15 US US11/435,301 patent/US7732165B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007525207A5 (enExample) | ||
| US7732165B2 (en) | Biomolecule partition motifs and uses thereof | |
| KR100645851B1 (ko) | 단백질 중공 나노 입자와 그것을 이용한 물질운반체, 및세포로의 물질도입방법 | |
| JP2010516758A5 (enExample) | ||
| CN109851674B (zh) | 一种用于治疗儿童矮小症的重组人血清白蛋白/生长激素融合蛋白的制备纯化方法 | |
| KR20110062997A (ko) | 유비퀴틴 또는 유비퀴틴-유사 단백질, 막 투과 도메인 및 생물학적 활성분자를 포함하는 융합 단백질 및 그의 용도 | |
| CN108610398B (zh) | 一段功能序列及在分泌蛋白表达中的应用 | |
| CN106432509B (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
| Zimmer et al. | The b1 Subunit but not the b2 Subunit Colocalizes with the Human Heart Na+ Channel (hH1) already within the Endoplasmic Reticulum. | |
| CN102875683B (zh) | 长效重组人生长激素的Fc融合蛋白 | |
| JP2001000194A (ja) | 神経成長因子を真核生物細胞において発現させるための遺伝子ベクター | |
| US10464984B2 (en) | Optimized nucleic acid sequences coding for the alpha-chain of human chorionic gonadotropin | |
| CN107460206A (zh) | 人fsh的重组表达载体、重组细胞株及重组人fsh的制备方法 | |
| US20100305040A1 (en) | Production of soluble recombinant protein by pi value control of n-terminal | |
| CN105524147A (zh) | 重组聚多肽及其应用 | |
| PT1870460E (pt) | Processo para produção de proteína possuindo uma estrutura de tripla hélice | |
| KR101442254B1 (ko) | 최적의 진핵 세포 발현 벡터의 개발 | |
| TWI225517B (en) | Genomic sequences for protein production and delivery | |
| JPWO2019236577A5 (enExample) | ||
| CN106008717B (zh) | 一种长效重组glp-1融合蛋白及其制备方法和用途 | |
| CN106715686A (zh) | 生产具有改性糖基化重组糖蛋白的方法 | |
| JP2003505043A (ja) | 血清アルブミンのキメラポリペプチド及びそれらに関する利用 | |
| TW200538547A (en) | A cell expressing a small peptide and production thereof and a method of expressing a small peptide | |
| WO2006052363A2 (en) | Co-expression of multiple protein chains or subunits | |
| JP2001513788A (ja) | 二重特異性、共刺激性を有するキメラタンパク質によるｔ−細胞増殖の共刺激 |